Patients with brain metastases from gastrointestinal cancers show worse survival after stereotactic radiosurgery than those ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, ...

Colorectal cancer is one of the most common types of tumor and is responsible for around 10% of cancer-related deaths ...

Scientists uncover surprising immune response that helps tumors grow, revealing new strategies to improve treatment ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...